.
MergerLinks Header Logo

New Deal


Announced

Virbac to acquire Sasaeah from ORIX for €280m.

Financials

Edit Data
Transaction Value£239m
Consideration TypeCash
Capital Owned-
Capital Bid For100%
EV/Sales-
EV/EBITDA-
Share Price Premium-
One Off Charge-

Tags

Edit

veterinary products

Japan

Pharmaceuticals

Acquisition

Cross Border

Majority

Private

Pending

Friendly

Single Bidder

Synopsis

Edit

Virbac, a pharmaceutical company, agreed to acquire Sasaeah, a veterinary products manufacturer, from ORIX, a Japanese diversified financial services group, for €280m. “Japan is a key market in the global animal health industry. This acquisition aligns seamlessly with our company's vision for 2030, emphasizing geographic expansion in major markets, the growth of our vaccines segment and the reinforcement of our key species. We are deeply honored to welcome the talented Sasaeah team to our global Virbac family. Together, we look forward to shaping the future of animal health in Japan,” Sébastien Huron, Virbac CEO.

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US